Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy


Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., ...More

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.6, pp.1163-1171, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 73 Issue: 6
  • Publication Date: 2014
  • Doi Number: 10.1007/s00280-014-2450-8
  • Journal Name: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1163-1171
  • Keywords: LDH, CEA, CA19-9, Metastatic, Pancreatic cancer
  • Istanbul University Affiliated: Yes

Abstract

Serum LDH, CEA, and CA19-9 levels are important tumor markers in pancreatic cancer. The purpose of this study was to evaluate the clinical significance of serum LDH, CEA, and CA19-9 levels in metastatic pancreatic cancer (MPC) receiving gemcitabine-based chemotherapy.